ARTICLE | Company News
Ocugen to go public via Histogenics reverse merger
April 11, 2019 8:54 PM UTC
Ocugen will reverse merge with Histogenics to form a public company focused on discovering, developing and commercializing therapies for rare eye diseases.
Ocugen Inc. (Malvern, Pa.) stockholders will own about 90% of the resulting company, which will trade on NASDAQ and be named Ocugen Inc. Histogenics Corp. (NASDAQ:HSGX) shareholders will own about 10%. The transaction is expected to close in late 2Q19 or 3Q19...